Top 10 Pharma MNCs To Hold 12% Of China Med Market, Up From 7%: IMS
This article was originally published in PharmAsia News
IMS has predicted that the top 10 U.S. and European multinational pharma will hold 12% of 17 emerging medical markets including China, up from 7% now.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.